CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis
|
|
- Francis Marshall
- 8 years ago
- Views:
Transcription
1 CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society of Canada (MSSC) are continuing their partnership aimed at accelerating preclinical development of novel therapies for Multiple Sclerosis (MS). To achieve this goal, the organizations together are seeking pre-proposals from academic investigators for collaborative projects aimed at developing new disease-modifying therapies for progressive MS. Such therapies may include novel approaches to effectively modulating the immune system, promoting remyelination, repairing existing damage and/or protecting neurons to positively impact the progressive forms of the disease. Background and Purpose In the past twenty years, there has been significant progress in the development of therapeutics for relapsing-remitting MS, resulting in ten Health Canada-approved disease-modifying therapies. Despite this success, patients living with progressive MS still have no effective diseasemodifying therapies available to them. Progressive MS is the slow accumulation of disability that either follows the relapsing-remitting stage (secondary progressive MS) or manifests without a history of acute attacks (primary progressive MS). Without treatment options, those living with progressive MS face an inevitable decline in health that usually begins during the most productive years of their lives. In collaboration with the MSSC, CDRD is seeking to build new collaborations that will facilitate and expedite the discovery and development of new disease-modifying therapies for the treatment of progressive MS. CDRD and the MSSC are looking to support preclinical development of novel therapeutic small molecules or biologics that will promote remyelination, stop or delay the progression of neuronal damage, repair accumulated damage to the CNS or modify disease progression in other ways. Also of interest are diagnostic biomarkers and new disease models which have the potential to expedite the preclinical and clinical
2 development of new therapeutics. New collaborative projects will have potential for clinical development yet have some critical outstanding questions that can be answered by collaborative experimental work in both the investigator s laboratory and at CDRD. Supporting New Collaborative Projects The partnership between CDRD and the MSSC represents an opportunity for researchers at the cutting edge of MS research to move their technologies through preclinical development and facilitate translation to patients. Please note that CDRD is NOT a granting agency. However, CDRD DOES provide drug development and commercialization expertise, specialized facilities and a fully-integrated development platform to enable researchers to identify and advance promising drug candidates in a collaborative manner. CDRD s platform supports each stage of the preclinical drug development process from target validation, highthroughput drug screening, medicinal chemistry and drug delivery to non- GLP pharmacology/toxicology. Our biologics division specializes in therapeutic antibodies, the fastest growing class of new medicines. Unlike traditional grant-in-aid or sponsored research grants which are typically developed by the investigator alone, CDRD will work with successful applicants to develop a full Collaborative Project Plan addressing the next critical activities that are required to progress the technology towards the clinic. This type of collaborative effort has been designed to enable academic investigators to advance development of their technologies much further than typical grant funding strategies would allow. Through these Collaborative Projects, CDRD and the MSSC seek to provide Investigators with access to expertise and infrastructure available at CDRD that complements the resources currently available to Investigators in order to maximize the chances of turning promising discoveries into clinical candidates. CDRD collaborators also have access to a dedicated and distinct commercialization vehicle, CDRD Ventures Inc. (CVI) which can subsequently bring additional commercialization resources (including further expertise, commercial mentorship, strategic partners, and seed funding) to the technology should CVI and the Investigator opt to enter into a further partnership. For more information please see
3 Who May Apply? Any academic investigator who is eligible under the policies of their host institution may submit a pre-proposal. To address any questions concerning eligibility or how CDRD and the MSSC may be able to help advance their discoveries, investigators are encouraged to contact Dr. Nicolette Honson (nhonson@cdrd.ca) before submitting their pre-proposal. Investigators who are interested in applying for an operating research grant should apply directly to the MSSC. Click here for more information. Intellectual Property Status It is not necessary to have filed a patent application in order to collaborate with CDRD. However, the technology that is the subject of a Collaborative Project must be unencumbered, i.e., rights in the technology cannot have been granted or optioned to a third party by the applicant or their host institution. CDRD Projects are collaborative in nature, and ownership of any new IP created in the course of a CDRD Project is determined by inventorship. In each of its projects, CDRD works with the Investigator and institution to bundle and maximize protection for the technology under development in order to establish a commercially attractive technology package that can attract further investment and interest in clinical development. Application and Review Process The review process will be managed by CDRD and guided by the input of additional experts nominated by the MSSC. March 31st 2015: Pre-proposal submission opens. April 30th 2015, 17:00 Pacific Standard Time: Pre-proposal submission closes. The pre-proposal submission is comprised of a project title and three-hundred word NON-CONFIDENTIAL summary (click here to download template). Please note that ALL PRE-PROPOSALS WILL BE TREATED AS NON-CONFIDENTIAL INFORMATION. Pre-proposals must be submitted electronically to msrfp@cdrd.ca. Early submission of the preproposal is encouraged. May 15th 2015: Notification of selection of successful pre-proposals. Applicants who have submitted a successful pre-proposal will be contacted by CDRD, and will be asked to enter into a confidentiality agreement with CDRD to enable submission of a subsequent full
4 Collaborative Project Proposal (template to be provided upon notification) June 1st 2015, 17:00 Pacific Standard Time: Deadline for submission of Collaborative Project Proposal. Proposals must be submitted electronically to June 30th 2015: Notification of selection of successful Collaborative Project Proposals. July 1st- August 31st 2015: Co-development of Collaborative Project Plan between investigators and CDRD. For technologies selected by CDRD and the MSSC, the investigator(s), in collaboration with CDRD, will develop a proposed Project Plan and budget to undertake the critical experiments needed to advance the technology. It is anticipated that activities outlined in the Collaborative Project Plan will encompass activities leveraging the infrastructure and expertise available at CDRD in addition to the expertise (e.g. unique models and assays) existing in the investigator s and potentially other collaborators laboratories. All Project Plans are subject to review by the MSSC s Medical Advisory Committee and approval by the MSSC s National Board of Directors prior to funding. October 2015: Anticipated project start date. For additional questions or assistance, please contact: Nicolette Honson, Ph.D. Project Search and Evaluation Team, nhonson@cdrd.ca +1 (604) The Centre for Drug Research and Development, 2405 Wesbrook Mall, Fourth Floor, Vancouver, BC, V6T 1Z3 About CDRD CDRD is Canada s fully-integrated national drug development and commercialization centre, providing expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates in a collaborative manner. Its mandate is to de-risk discoveries stemming from publiclyfunded health research and transform them into viable investment
5 opportunities for the private sector thus successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients. Canada s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). About the MSSC Canada has the highest rate of multiple sclerosis in the world. MS is a chronic, often disabling disease of the brain and spinal cord. It is the most common neurological disease of young adults in Canada. Most people with MS are diagnosed between the ages of 15 and 40, and the unpredictable effects of MS last for the rest of their lives. The MSSC provides services to people with MS and their families and funds research to find the cause and cure for this disease. Please visit mssociety.ca or call for more information. Conditions This call for Collaborative Projects and your submission of a pre-proposal does not commit CDRD or the MSSC to select any Collaborative Project or Applicant, to enter into any agreements with any Applicant or to conduct any project with any Applicant. CDRD and the MSSC reserve the right to reject any or all Collaborative Project Proposals at any time, and to terminate this call for Collaborative Projects at any time. In providing CDRD personal information in the course of your application, you consent to the collection and use by CDRD, CDRD Ventures Inc., and the MSSC of such information for the purposes of evaluating, awarding, and managing relevant projects. We will use and protect personal information in accordance with applicable privacy law.
AUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationJ D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S
J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with
More informationNATIONAL POPULATION HEALTH STUDY OF NEUROLOGICAL CONDITIONS. Invitation To Submit A Letter Of Intent (LOI) Guide To Applicants
Enhanced Surveillance for Chronic Disease Program NATIONAL POPULATION HEALTH STUDY OF NEUROLOGICAL CONDITIONS Invitation To Submit A Letter Of Intent (LOI) Guide To Applicants January 2010 Table of Contents
More informationHow To Get A Grant From Kinesis
- The collaboration initiative to move drug candidates forward Introduction What are we offering? How? Why apply? Terms Background For grant applications and to attract venture capital start-up companies
More informationMultiple Myeloma Research Foundation. 2015 Senior Research Award. Program Guidelines
Multiple Myeloma Research Foundation 2015 Senior Research Award Program Guidelines MULTIPLE MYELOMA RESEARCH FOUNDATION 2015 SENIOR RESEARCH AWARD Program Description: The Multiple Myeloma Research Foundation
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationJ D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H
J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H PURPOSE JDRF, the world s leading non-profit organization
More informationThe Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder
The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system
More information2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
More informationMultiple Myeloma Research Foundation. 2015 Research Fellow Award. Program Guidelines
Multiple Myeloma Research Foundation 2015 Research Fellow Award Program Guidelines Program Description: MULTIPLE MYELOMA RESEARCH FOUNDATION 2015 RESEARCH FELLOW AWARD The Multiple Myeloma Research Foundation
More informationTestimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC
Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Committee on Oversight and Government Reform Domestic Policy Subcommittee U.S. House of
More informationAlberta/Novartis Translational Research Fund Opportunity. Program Guide 2014/2015
OBJECTIVES Program Guide 2014/2015 Alberta Innovates - Health Solutions (AIHS), Novartis Pharmaceuticals Canada Inc. (Novartis), and the Government of Alberta have partnered to create the Alberta/Novartis
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationTop Ten Things to Know About Stem Cell Treatments
Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationA Guide to the ABTA s 2013 Medical Student Summer Fellowship Application
A Guide to the ABTA s 2013 Medical Student Summer Fellowship Application Please be aware the submission process has changed. All applications for the 2013 American Brain Tumor Association Medical Student
More informationRE AP QUE PLIC FOR IONS. Compa CPRIT RFA C 12 FORM 2. Company. p.1/17
RE AP QUE ST PLIC AT RFA C 12 FORM 2 FOR IONS Compa any Formation Awards FY 2012 Fiscal Year Award Period September 1, 2011 Augustt 31, 2012 CPRIT RFA C 12 FORM 2 (Rev 6/ /30/11) Company Formation Awards
More information2015 AriSLA Ice Bucket Call for Clinical Projects
2015 AriSLA Ice Bucket Call for Clinical Projects Deadline: at 1.00 pm, May 12 th, 2015 1. Background AriSLA, Italian Foundation for research on ALS Amyotrophic Lateral Sclerosis, opens its 2015 Call for
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationCall 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationNortheast Ohio Medical University (NEOMED) Chair of Pharmaceutical Sciences Search
Northeast Ohio Medical University (NEOMED) Chair of Pharmaceutical Sciences Search Spring 2013 About NEOMED Northeast Ohio Medical University (NEOMED) www.neomed.edu is a dynamic free-standing community-based,
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More information2015/2016. Heart and Stroke Foundation New Investigator Awards Guidelines Alberta. (Winter 2014 Competition)
2015/2016 Heart and Stroke Foundation New Investigator Awards Guidelines Alberta (Winter 2014 Competition) November, 2014 Heart and Stroke Foundation New Investigator Awards in Alberta The Heart and Stroke
More informationA Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationCrohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease
Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals Sponsored Research Program in Inflammatory Bowel Disease Presentation Overview Background on inflammatory bowel disease Partner Overview
More informationFiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award
More informationIssues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?
ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in
More informationMission The mission of the Alliance for Lupus Research is to prevent, treat and cure lupus through medical research.
ALLIANCE FOR LUPUS RESEARCH TARGET IDENTIFICATION IN LUPUS APPLICATION PROGRAM GUIDELINES Effective June 5, 2014 Letter of Intent Due July 10, 2014 APPLICATION DUE DATE August 25, 2014 Applications will
More informationAST Transplantation and Immunology Research Network (TIRN) 2016 Allied Health Professional Research Grant
AST Transplantation and Immunology Research Network (TIRN) 2016 Allied Health Professional Research Grant If you have any questions, please email TIRN@myAST.org. The application deadline is 11:59 pm Pacific
More informationMSc in Tissue Engineering One year full-time
Cardiff Institute of Tissue Engineering and Repair (CITER) MSc in Tissue Engineering One year full-time What is Tissue Engineering? "Tissue engineering is an interdisciplinary field combining life and
More informationMaking the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationPrecision Medicine Challenge Centralized Pharmacogenomic Recruitment Database
Precision Medicine Challenge Centralized Pharmacogenomic Recruitment Database March 13, 2016 Table of Contents Key Proposal Elements Strategic Considerations Page 2 Key Proposal Elements Current Trial
More informationClinical Trials. Helpful information and answers for patients
Clinical Trials Helpful information and answers for patients I joined a clinical trial because I want to make it a better world for my daughter and grandchildren. Hopefully, by the time they re old enough
More informationNational Cancer Institute
Technology Transfer Center National Cancer Institute NCI Shady Grove 9609 Medical Center Dr. Room 1E-530, MSC 9702 Bethesda, MD 20892-9702 Telephone: 240-276-5530 Fax: 240-276-5504 Technology Transfer
More informationPharmaceutical & Chemical Sciences Graduate Program
Pharmaceutical & Chemical Sciences Graduate Program Pharmaceutical and Chemical Sciences Graduate Program Program Goals and Design: The mission of the Pharmaceutical and Chemical Sciences Graduate Program
More informationSTEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.
STEM CELL FACTS The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. WHAT ARE STEM CELLS? Stem cells are the foundation cells for
More informationThe Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationCord Blood Bank Business Plan
Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page
More informationThe Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
More informationBN201: a paradigm-shift (neuroprotection) in the treatment of neurodegenerative diseases
Programa Cooperación Farma-Biotech 9º encuentro (4 de julio de 2013) BN201: a paradigm-shift (neuroprotection) in the treatment of neurodegenerative diseases Barcelona, 4 de julio de 2013 Programa Cooperación
More informationUnderstanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
More informationIntellectual Property. MGPA s Industry Experience program Spring 2012
Intellectual Property MGPA s Industry Experience program Spring 2012 Intellectual Property (IP): Legal Protection for Intangible Assets Copyright Patent Trademark and Trade Secrets 2 Copyright Creative
More informationPA 14-01: CIRM Accelerated Development Pathway
PA 14-01: CIRM Accelerated Development Pathway I. Purpose Through the Disease Team (Disease Team Research or Therapy Development) and Strategic Partnership Award programs, the California Institute for
More informationPART I. SECTION 1. The legislature finds that an estimated. 128,000,000 Americans suffer from the crippling economic and
HOUSE OF REPRESENTATIVES TWENTY-FOURTH LEGISLATURE, 2007 STATE OF HAWAII A BILL FOR AN ACT RELATING TO MEDICAL RESEARCH. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: PART I SECTION 1. The legislature
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationEVT Execute & EVT Innovate World-class drug discovery
EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,
More informationAACR Team Science Award
2015 Program Guidelines and Nomination Instructions AMERICAN ASSOCIATION FOR CANCER RESEARCH 17th Floor, 615 Chestnut Street Philadelphia, PA 19106-4404 (215) 440-9300 (267) 765-1047 (FAX) www.aacr.org/scientificawards
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationBusiness process overview and due diligence checklist to assess new small business funding opportunities
Business process overview and due diligence checklist to assess new small business funding opportunities Foundations that fund medical research increasingly have and are taking the opportunity to fund
More informationMany people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).
Complementary and alternative medicine (CAM) CAM therapies can generally be divided into the following categories: Biologically based therapies (eg, dietary supplements, diets, bee venom therapy, hyperbaric
More informationMRC Technology Centre for Therapeutics Discovery
MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established
More informationHow To Change Medicine
P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version
More information10% ACADEMIC-90% ENTREPRENEUR
ERIC CLAASSEN 10% ACADEMIC-90% ENTREPRENEUR CHAIR Businessmanagement and Entrepreneurship in the Life Sciences VRIJE UNIVERSITEIT Amsterdam (2001..) MEDICAL FACULTY ERASMUS UNIVERSITY ROTTERDAM (1994.)
More informationHow To Make A Successful Business From A Successful Research Project At Uni
Working with UCL Business in The Realisation of Research CNS technologies Dr Abbie Watts Senior Business Manager Biopharm UCL Business PLC Working with UCL Business in CNS technologies Introduction to
More information2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
More informationCURESEARCH FOR CHILDREN S CANCER AND GATEWAY FOR CANCER RESEARCH COMMUNITY IMPACT AWARD - CLINICAL TRIALS
KEY DATES Request for Applications Opens: June 3, 2015 Application Due: August 3, 2015 Award Notification: September 2015 Award Period : October 2015 October 2016 CURESEARCH FOR CHILDREN S CANCER AND GATEWAY
More informationINVESTIGATOR-INITIATED RESEARCH GRANTS
Because breast cancer is everywhere, SO ARE WE. At Susan G. Komen for the Cure, we are committed to ENDING breast cancer forever by ENERGIZING SCIENCE to find the cures and ensuring QUALITY CARE for all
More informationVenture Development Fund Request for Proposals
Venture Development Fund Request for Proposals Summary Oregon State University seeks to facilitate the further development of OSU applied innovations and commercialization. The purpose of this RFP is to
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationA Real Time Lab for Pan Canadian Innovation Leveraging Canadian Blood Services Model for Better Value to Health care Systems
A Real Time Lab for Pan Canadian Innovation Leveraging Canadian Blood Services Model for Better Value to Health care Systems November 14, 2014 Submission to the Advisory Panel on Health Care Innovation
More informationNational curriculum and assessment guidelines in preparation for registration as a Medical Biological Scientist
National curriculum and assessment guidelines in preparation for registration as a Medical Biological Scientist National curriculum Medical Biological Scientists Last Modified March 2013 Page 1 of 9 1.
More informationVision 2020 Strategic Plan
UNIVERSITY OF HOUSTON COLLEGE OF PHARMACY Vision 2020 Strategic Plan A VISION OF THE FUTURE Caring for Texans through health and discovery The college will be a leader in education, research, service and
More informationUC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review Cindy Gates IRB Administration Tips for Reviewer s Comments - Comments should be easily transferrable
More informationCautionary Statement
Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and
More informationThe University of Cincinnati is an affirmative action/equal opportunity employer.
Position #214UC7312 The University of Cincinnati James L. Winkle College of Pharmacy invites applications for a full- time, non- tenure track, 12- month clinical faculty position in the Division of Pharmacy
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More information1) SCOPE OF THE PROGRAM
CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany
More informationUniversity of Calgary Mitacs Accelerate Internship Terms & Non Disclosure Agreements
University of Calgary Mitacs Accelerate Internship Terms & Non Disclosure Agreements This package includes the following: The Mitacs Accelerate Internship Terms for all internships at The University of
More informationA vaccine for rheumatoid arthritis
A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright
More informationONLINE APPLICATION GUIDELINES Last Updated: December 9, 2015
endms Scholar Program for Researchers IN Training (SPRINT) ONLINE APPLICATION GUIDELINES Last Updated: December 9, 2015 Multiple Sclerosis Society of Canada Research Department 500-250 Dundas Street West
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationNovel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405
More informationADULT HEALTH AND WELLBEING LONG-TERM NEUROLOGICAL CONDITIONS
ADULT HEALTH AND WELLBEING LONG-TERM NEUROLOGICAL CONDITIONS i. Summary The National Service Framework for long-term neurological conditions categorises neurological conditions as: Sudden-onset conditions
More informationMultiple Sclerosis Treatments: World Market Outlook to 2011
Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationElectronic data interchange and proactive services for Centricity revenue cycle management customers
GE Healthcare Electronic data interchange and proactive services for Centricity revenue cycle management customers Accelerate revenue perf Key features Tight alignment with payers ensures mandates, updates
More informationCAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
More informationBackground Information
Background Information 1. What are stem cells? 2. What might stem cell research achieve? 3. Why we need to continue research using embryonic stem cells? 4. Time taken for discoveries 5. Examples of stem
More informationGE Healthcare. Electronic data interchange and proactive services for Centricity revenue cycle management customers
GE Healthcare Electronic data interchange and proactive services for Centricity revenue cycle management customers Accelerate revenue perf Key features updates and other payer-specific adjustments are
More informationresearch center concept
research center concept research center concept 1 Overview As a key part of the Russian Skolkovo Initiative, the Skolkovo Foundation, MIT, and others are assisting in the creation of the Skolkovo Institute
More informationMultiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationthe future in your hands imagine
the future in your hands imagine The promise of hope Carrie and Wilf s story... Quinn weighed in at a healthy 4397g at birth. His parents, Carrie and Wilf, had decided to store the umbilical cord blood
More informationPharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
More informationAnforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research
Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationProcedure for Requesting Biological Samples and Data from the Accelerated Cure Project MS Repository
Procedure for Requesting Biological Samples and Data from the Accelerated Cure Project MS Repository March 2009 The Accelerated Cure Project Blood, Tissue and Data Bank solicits proposals requesting biological
More informationStem Cells and Hope for Patients
Stem Cells and Hope for Patients by Maureen Condic, Ph.D. Most Americans know someone afflicted with an incurable medical condition. The possibility of stem cell cures has given hope to many who face such
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationGates Vaccine Innovation Award Rules & Guidelines
Gates Vaccine Innovation Award Rules & Guidelines Nominations due by Friday, August 31, 2012, 11:59pm, U.S. Pacific Daylight Time Overview At the World Health Assembly in May, 2011, Bill Gates, co-chair
More informationEquitable Choice. Ensuring affordability and accessibility to drug therapies
Equitable Choice Ensuring affordability and accessibility to drug therapies Equitable Choice - Ensuring affordability & accessibility to drug therapies Equitable Choice: Ensuring affordability and accessibility
More informationKentucky Lung Cancer Research Program. 2010 Strategic Plan Update
Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated
More information